WP
RPRX icon

Woodline Partners’s Royalty Pharma RPRX Stock Holding History

Woodline Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
23,330
+7,575
+48% +$394K ﹤0.01% 887
2026
Q1 		$756K Buy
15,755
+8,319
+112% +$364K ﹤0.01% 913
2025
Q4 		$287K Buy
+7,436
New +$284K ﹤0.01% 961

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's RPRX Position: Q2 2026 in Review

Woodline Partners increased its Royalty Pharma (RPRX) stake by 48% in Q2 2026, buying an estimated $394K and bringing the position to 23,330 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Woodline Partners first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Woodline Partners held 23,330 shares of Royalty Pharma worth $1.31M as of Q2 2026.
  • Woodline Partners bought 7,575 Royalty Pharma shares in Q2 2026, an estimated $394K.
  • Royalty Pharma made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #887 holding.
  • Woodline Partners first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.